SCHEMBL6500907

SCHEMBL6500907

CC(C)(C)OC(=O)Nc1cccc(CCN(C(=O)OC(C)(C)C)c2ccc([N+](=O)[O-])cc2)n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 3/20 0.39
MMP2 P08253 3/20 0.39
MMP9 P14780 3/20 0.39
MMP8 P22894 3/20 0.39
MMP13 P45452 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MAPT P10636 2/20 0.38
ALOX5 P09917 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SLC29A1 Q99808 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
BCL2 P10415 1/20 0.35
BECN1 Q14457 1/20 0.35
MAPK1 P28482 1/20 0.35
NR3C2 P08235 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489886 0.86 NR3C2 (0.39) NR3C2
SCHEMBL6489918 0.82 ALDH1A1 (0.43) MMP1MMP2MMP9MMP8MMP13
SCHEMBL6497053 0.81 NPC1 (0.46) MMP1MMP2MMP9MMP8MMP13
SCHEMBL6487610 0.81 MAPT (0.48) NPC1RAB9AMAPTALDH1A1KMT2A
SCHEMBL6489438 0.80 POLB (0.51) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL6677518 0.79 NR3C2 (0.39) KMT2AMEN1NR3C2
SCHEMBL6800939 0.77 GAA (0.42) ALDH1A1
SCHEMBL6645809 0.77 RAB9A (0.34) NPC1RAB9AMAPTALDH1A1
SCHEMBL6501746 0.77 HDAC1 (0.37) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL6499366 0.76 NR3C2 (0.37) NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 MMP1 968/4885MMP2 1781/4885MMP9 1344/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MMP1 779/4885MMP2 1058/4885MMP9 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.